The statements reached high consensus for testing for germline PALB2 mutations and including BRCA1 and BRCA2 genes in the gene panel for therapeutic indications in high risk HER2-negative eBC patients; considering patients with likely/pathogenic variants in BRCA for risk reduction surgery; undergoing regular BC surveillance, including self-examinations and clinical breast exams in healthy carriers; providing benefits from PARPi for metastatic patients with somatic BRCA pathogenic variants (Statements 17 to 22, Table 4). The gene discussed is BRCA2; the disease is breast cancer.